A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Conditions
Anaplastic Large Cell Lymphoma (ALCL) | Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) | Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral | other transformed T-cell lymphomas
What is the purpose of this trial?
The drug being studied in this research study is called sorafenib (Nexavar). Sorafenib is a standard therapy approved by the United States Food and Drug Administration (FDA) to treat renal cell (kidney) cancer, and hepatocellular (liver) cancer. It is not approved for use in lymphoma, however, the FDA does permit its use in studies like this one where we look at biomarkers to see what effects this drug has on you and your cancer. Sorafenib is a drug that stops the growth of cancer cells and prevents the formation of new blood vessels that would normally help the cancer survive and spread. The study in which you are now being asked to participate is the first study to examine use of sorafenib in participants with T-cell lymphoma who have been treated with at least one prior therapy but the disease has gotten worse, has not gone away, or came back after treatment with other medicines.Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Bayer
Yale Cancer Center - Dates:
- October 2009
- Last Updated:
- Study HIC#:
- 0901004690
Clinicaltrials.gov ID: Yale5062786
For more information about this trial, contact:
Investigator
Francine Foss, MD
Principal Investigator
